WO2009040067A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents
Utilisation d'un peptide en tant qu'agent thérapeutique Download PDFInfo
- Publication number
- WO2009040067A3 WO2009040067A3 PCT/EP2008/007938 EP2008007938W WO2009040067A3 WO 2009040067 A3 WO2009040067 A3 WO 2009040067A3 EP 2008007938 W EP2008007938 W EP 2008007938W WO 2009040067 A3 WO2009040067 A3 WO 2009040067A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- phe
- gly
- arg
- gln
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
Abstract
La présente invention concerne l'utilisation du composé peptidique Tyr-Gly-Gly-Phe- Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly- Glu-Leu-Phe-Asp-Ala-OH en tant qu'agent thérapeutique destiné à la prophylaxie et/ou au traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodégénératives, de maladies infectieuses, de maladies pulmonaires, de maladies cardiaques et vasculaires et de maladies métaboliques. Cette invention concerne aussi des compositions pharmaceutiques, de préférence sous la forme d'un lyophilisat, d'une solution tampon liquide ou d'une préparation de lait maternel artificiel ou d'un substitut du lait maternel contenant le peptide Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe- Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala-OH, éventuellement avec au moins un véhicule, un cryoprotecteur, un lyoprotecteur, un excipient et/ou un diluant pharmaceutiquement acceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017757 | 2007-09-11 | ||
EP07017757.1 | 2007-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009040067A2 WO2009040067A2 (fr) | 2009-04-02 |
WO2009040067A3 true WO2009040067A3 (fr) | 2009-09-24 |
Family
ID=40428261
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007963 WO2009033779A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007938 WO2009040067A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007623 WO2009043452A1 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007797 WO2009033749A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide comme agent thérapeutique |
PCT/EP2008/007666 WO2009033729A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007453 WO2009033666A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007431 WO2009033656A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007963 WO2009033779A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007623 WO2009043452A1 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007797 WO2009033749A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide comme agent thérapeutique |
PCT/EP2008/007666 WO2009033729A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007453 WO2009033666A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
PCT/EP2008/007431 WO2009033656A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
Country Status (8)
Country | Link |
---|---|
US (5) | US20100184673A1 (fr) |
EP (5) | EP2190463A2 (fr) |
JP (4) | JP2010538985A (fr) |
KR (4) | KR20100056516A (fr) |
AU (5) | AU2008306257A1 (fr) |
CA (5) | CA2698980A1 (fr) |
RU (5) | RU2010114008A (fr) |
WO (7) | WO2009033779A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530420B2 (en) | 2008-12-16 | 2013-09-10 | Kaohsiung Medical University | Treatment of arthritis with parathyroid hormone |
EP2671889B1 (fr) * | 2010-04-02 | 2018-09-12 | The Regents Of The University Of Michigan | Peptides dérivés de rf-amide et procédés associés |
CN103386115B (zh) * | 2012-05-11 | 2015-11-25 | 浙江华尔成生物药业股份有限公司 | 胸腺五肽在制备治疗乳房炎药物中的应用 |
EP3515470B1 (fr) * | 2016-09-21 | 2023-06-14 | Agency for Science, Technology and Research | Procédés pour prédire une inflammation cutanée et déterminer une susceptibilité au cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020304A2 (fr) * | 2001-09-03 | 2003-03-13 | The University Of Bristol | Compose modulateur d'inflammation |
EP1466610A1 (fr) * | 2001-11-26 | 2004-10-13 | Daiichi Suntory Pharma Co., Ltd. | Compositions medicales pour absorption nasale |
WO2006086653A2 (fr) * | 2005-02-08 | 2006-08-17 | Microbia, Inc. | Procedes et compositions pour le traitement de troubles gastro-intestinaux |
US20070010451A1 (en) * | 2005-07-07 | 2007-01-11 | Lee Byoung D | Method of protecting cells against damage and pharmaceutical composition comprising leumorphin |
WO2008052043A2 (fr) * | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Protéines de fusion agonistes du récepteur opioïde |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190646A (en) * | 1975-11-11 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptide compositions and methods |
US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
SE454513B (sv) * | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
US5547936A (en) * | 1985-06-17 | 1996-08-20 | La Jolla Cancer Research Foundation | Inhibition of cell migration with synthetic peptides |
US4749690A (en) * | 1986-01-27 | 1988-06-07 | Ortho Pharmaceutical Corporation | Treatment of allergy with thymopentin |
DK15888D0 (da) * | 1988-01-14 | 1988-01-14 | Carlsberg Biotechnology Ltd | Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden |
WO1989009229A1 (fr) * | 1988-03-31 | 1989-10-05 | Immunobiology Research Institute, Inc. | Traitement de patient atteint de viremie du hiv a l'aide de thymopentine |
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US5036050A (en) * | 1989-01-12 | 1991-07-30 | Immunobiology Research Institute, Inc. | Compositions containing thymopentin for topical treatment of skin disorders |
IT1238231B (it) * | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori |
US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
US6017877A (en) * | 1990-04-06 | 2000-01-25 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
ATE160486T1 (de) | 1991-08-12 | 1997-12-15 | Nestle Sa | Nahrungsmittelzusammensetzung |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
US5556940A (en) * | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
DK0832565T3 (da) | 1996-09-24 | 2000-11-20 | Nestle Sa | Mælkeerstatningsprodukt og fremgangsmåde til fremstilling deraf |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
ATE271783T1 (de) | 1998-11-24 | 2004-08-15 | Nestle Sa | Verfahren zur herstellung einer proteinzusammenzetzung und einer diese enthaltenden säuglingsnahrung |
CN1301740A (zh) * | 1999-12-24 | 2001-07-04 | 上海博德基因开发有限公司 | 一种新的多肽——甲状旁腺激素9和编码这种多肽的多核苷酸 |
EP1262190A4 (fr) * | 2000-03-06 | 2004-03-17 | Takeda Chemical Industries Ltd | Agent de regulation de la secretion de prolactine contenant du rfrp |
GB0016441D0 (en) * | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
SI1598340T1 (sl) * | 2001-04-18 | 2009-08-31 | Euro Celtique Sa | Derivati 1-(4-piperidinil)-1,3-dihidro-2H-benzoksazol-2-ona in sorodne spojine kot analogi nociceptina in ligandi ORL1 za zdravljenje bolečine |
ATE362707T1 (de) | 2001-11-23 | 2007-06-15 | Nestle Sa | Verfahren zur herstellung von milchpulver und konzentrierten milchprodukten |
GB0208499D0 (en) | 2002-04-12 | 2002-05-22 | Microscience Ltd | Streptococcal genes |
EP1837031B1 (fr) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methodes et compositions pour le traitement du diabete |
AU2003253014A1 (en) * | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
US7517661B2 (en) * | 2003-04-23 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Methods of screening for ligands for FPRL2 |
EP1628978A2 (fr) * | 2003-05-23 | 2006-03-01 | Zealand Pharma A/S | Analogues de nociceptine et leurs utilisations |
AU2005207870B2 (en) * | 2004-01-30 | 2010-08-19 | Waratah Pharmaceuticals, Inc. | The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels |
CA2571957A1 (fr) * | 2004-07-01 | 2006-01-12 | Waratah Pharmaceuticals, Inc. | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete |
US20060281670A1 (en) * | 2005-06-10 | 2006-12-14 | Wisconsin Alumni Research Foundation (Warf) | Compositions and methods for modulating angiogenesis |
AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
WO2007044069A2 (fr) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Formulations de pth et procedes d'utilisation |
EA026670B1 (ru) | 2006-03-10 | 2017-05-31 | Лабосвисс Аг | Способ солюбилизации, диспергирования и стабилизации веществ, продукты, полученные этим способом, и их применение |
-
2008
- 2008-09-09 RU RU2010114008/15A patent/RU2010114008A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802320A patent/EP2190463A2/fr not_active Withdrawn
- 2008-09-09 JP JP2010523356A patent/JP2010538985A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007963 patent/WO2009033779A2/fr active Application Filing
- 2008-09-09 US US12/676,903 patent/US20100184673A1/en not_active Abandoned
- 2008-09-09 AU AU2008306257A patent/AU2008306257A1/en not_active Abandoned
- 2008-09-09 CA CA2698980A patent/CA2698980A1/fr not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007938 patent/WO2009040067A2/fr active Application Filing
- 2008-09-09 EP EP08802205A patent/EP2185181A2/fr not_active Withdrawn
- 2008-09-09 JP JP2010523390A patent/JP2010539017A/ja active Pending
- 2008-09-09 KR KR1020107005629A patent/KR20100056516A/ko not_active Application Discontinuation
- 2008-09-09 EP EP08801994A patent/EP2185172A2/fr not_active Withdrawn
- 2008-09-09 RU RU2010114035/15A patent/RU2010114035A/ru not_active Application Discontinuation
- 2008-09-09 AU AU2008297524A patent/AU2008297524A1/en not_active Abandoned
- 2008-09-09 US US12/677,301 patent/US20100210557A1/en not_active Abandoned
- 2008-09-09 EP EP08835232A patent/EP2205267A1/fr not_active Withdrawn
- 2008-09-09 KR KR1020107005579A patent/KR20100056506A/ko not_active Application Discontinuation
- 2008-09-09 RU RU2010113993/15A patent/RU2010113993A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,349 patent/US20100210554A1/en not_active Abandoned
- 2008-09-09 CA CA2698855A patent/CA2698855A1/fr not_active Abandoned
- 2008-09-09 AU AU2008297903A patent/AU2008297903A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007623 patent/WO2009043452A1/fr active Application Filing
- 2008-09-09 RU RU2010114003/15A patent/RU2010114003A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,514 patent/US20100204156A1/en not_active Abandoned
- 2008-09-09 RU RU2010114055/15A patent/RU2010114055A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802014A patent/EP2190461A2/fr not_active Withdrawn
- 2008-09-09 US US12/676,919 patent/US20100197602A1/en not_active Abandoned
- 2008-09-09 JP JP2010523346A patent/JP2010538976A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007797 patent/WO2009033749A2/fr active Application Filing
- 2008-09-09 CA CA2699067A patent/CA2699067A1/fr not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007666 patent/WO2009033729A2/fr active Application Filing
- 2008-09-09 AU AU2008297926A patent/AU2008297926A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005617A patent/KR20100059858A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007453 patent/WO2009033666A2/fr active Application Filing
- 2008-09-09 CA CA2698759A patent/CA2698759A1/fr not_active Abandoned
- 2008-09-09 AU AU2008297936A patent/AU2008297936A1/en not_active Abandoned
- 2008-09-09 JP JP2010523397A patent/JP2010539024A/ja active Pending
- 2008-09-09 CA CA2698963A patent/CA2698963A1/fr not_active Abandoned
- 2008-09-09 KR KR1020107005586A patent/KR20100057045A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007431 patent/WO2009033656A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020304A2 (fr) * | 2001-09-03 | 2003-03-13 | The University Of Bristol | Compose modulateur d'inflammation |
EP1466610A1 (fr) * | 2001-11-26 | 2004-10-13 | Daiichi Suntory Pharma Co., Ltd. | Compositions medicales pour absorption nasale |
WO2006086653A2 (fr) * | 2005-02-08 | 2006-08-17 | Microbia, Inc. | Procedes et compositions pour le traitement de troubles gastro-intestinaux |
US20070010451A1 (en) * | 2005-07-07 | 2007-01-11 | Lee Byoung D | Method of protecting cells against damage and pharmaceutical composition comprising leumorphin |
WO2008052043A2 (fr) * | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Protéines de fusion agonistes du récepteur opioïde |
Non-Patent Citations (6)
Title |
---|
BALDWIN B A ET AL: "Effects of intracerebroventricular injection of dynorphin, leumorphin and alpha neo-endorphin on operant feeding in pigs", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 48, no. 6, 1 December 1990 (1990-12-01), pages 821 - 824, XP024318068, ISSN: 0031-9384, [retrieved on 19901201] * |
JESSOP DAVID S: "Endomorphins as agents for the treatment of chronic inflammatory disease", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 20, no. 3, 1 January 2006 (2006-01-01), pages 161 - 166, XP009114483, ISSN: 1173-8804 * |
LEE BYOUNG DAE ET AL: "Leumorphin has an anti-apoptotic effect by activating epidermal growth factor receptor kinase in rat pheochromocytoma PC12 cells", JOURNAL OF NEUROCHEMISTRY, WILEY INTERSCIENCE, NEW YORK, NY, US, vol. 95, no. 1, 1 October 2005 (2005-10-01), pages 56 - 67, XP002519845, ISSN: 0022-3042 * |
MAKULSKA-NOWAK H E ET AL: "Effects of endomorphin-2 on arterial blood pressure and pain threshold in spontaneously hypertensive rats and modification of these effects by beta-funaltrexamine and nor-binaltorphimine", LIFE SCIENCES 22 JUN 2001,, vol. 69, no. 5, 22 June 2001 (2001-06-22), pages 581 - 589, XP002539305 * |
SUDA M ET AL: "Human leumorphin is a potent, kappa opioid receptor agonist", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 50, no. 1-3, 7 September 1984 (1984-09-07), pages 49 - 52, XP024096818, ISSN: 0304-3940, [retrieved on 19840907] * |
SZEGEDI V ET AL: "Endomorphin-2, an endogenous tetrapeptide, protects against A[beta]1-42 in vitro and in vivo", FASEB JOURNAL 200606 US,, vol. 20, no. 8, 1 June 2006 (2006-06-01), pages E324 - E333, XP002539304 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009033734A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009033740A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009033796A8 (fr) | Peptide utilisé comme agent thérapeutique | |
WO2009040019A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009043507A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033805A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033717A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009040004A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033733A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009039973A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033765A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009033767A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009039976A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033741A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009040017A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009040073A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009039986A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033754A8 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
WO2009033786A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009043469A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009040067A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802442 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 203837 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08802442 Country of ref document: EP Kind code of ref document: A2 |